The global healthcare market is undergoing transformative change with underlying growth drivers including ageing populations, increased wealth in emerging markets and trends towards patient centrism, digitalisation and innovation.
Nordic Capital is one of the most active and experienced investors in healthcare globally, focusing on investing in companies throughout the healthcare space with potential to grow and expand into new markets and industry-leading innovations or value propositions.
Learn more about Nordic Capital's healthcare focus in this video:
44
healthcare platform investments since 1990*
€10.8bn
of equity capital deployed in the sector*
46,700
people employed by Nordic Capital-backed healthcare companies**
€8.6bn
of revenues generated in current healthcare portfolio**
Investment Director
Managing Director, Country Coverage Manager for Denmark
Partner | Co-Head of Healthcare | Head of U.S.
Operations Managing Director
Operations Managing Director
Partner, Co-Head of Evolution advisory
Partner
Partner, Co-Head of Evolution advisory
Investment Director
Investment Director
Investment Director
Partner
Partner | Head of DACH
Partner | Head of Healthcare | Head of UK
Investment Director
Partner
Managing Director
Managing Director
Since acquiring Advanz Pharma in 2021, Nordic Capital has supported the global pharmaceutical company’s growth and expansion agenda beyond Europe. Steffen Wagner, CEO, discusses the learnings to date and how Nordic Capital have supported Advanz Pharma’s ambition to become the partner of choice for specialty hospitals and rare disease pharmaceuticals.
During Nordic Capital’s four-year ownership period, Nordic Capital helped AniCura to grow fourfold, shaping the European vet care landscape by creating a specialised clinic business with high quality pet care at its core. It increased the number of its clinics from 50 to over 200, its employees numbers from 1,000 to 4,000 and its pro forma revenues from approx. SEK 0.9 bn to SEK 3.3 bn.
* Deal count and equity capital including Evolution Fund I and cross-sector investments (e.g. HealthTech); cross-fund investments counted as one. Excluding CV1
** Including HealthTech companies
